Business
Cardiol Therapeutics to Present at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference
Oakville, Ontario--(Newsfile Corp. - September 15, 2020) - Cardiol Therapeutics Inc. ( TSX:...
About this update from Cardiol Therapeutics Inc. Class A
[{"type":"text","content":"Cardiol Therapeutics to Present at the H.C. Wainwright Virtual 22nd Annual Global Investment ConferenceOakville, Ontario--(Newsfile Corp. - September 15, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (\"Cardiol\" or the \"Company\"), a leader in the development of pharmaceutical cannabidiol formulations for the treatment of cardiovascular diseases, including heart failure and acute myocarditis, announces that Cardiol's President and CEO, Mr. David Elsley, will present a company overview at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference today at 12:00 PM EDT.A live webcast and replay of the presentation will be accessible on the Company's website section https://www.cardiolrx.com/investors/events-presentations/About Cardiol TherapeuticsCardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) is a leader in the development of pharmaceutical cannabidiol formulations for the treatment of cardiovascular diseases, including heart failure and acute myocarditis. The Company's lead product, CardiolRx™, is pharmaceutically produced, manufactured under cGMP, and is THC free (<5 ppm). Cardiol is planning a Phase II international trial of CardiolRx™ in acute myocarditis, a condition caused by inflammation in heart tissue, which remains the most common cause of sudden cardiac death in people less than 35 years of age. The Company is also developing proprietary cannabidiol formulations for the treatment of inflammation in the heart that is associated with the development and progression of heart failure. Heart failure is the leading cause of death and hospitalization in North America, with associated annual healthcare costs in the U.S. alone exceeding $30 billion. For further information about Cardiol Therapeutics, please visit cardiolrx.com.For further information, please contact:David Elsley, President & CEO [email protected] Burns, Investor Relations [email protected] Cautionary statement regarding forward-looking information:This news release contains \"forward-looking information\" within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol Therapeutics Inc. (\"Cardiol\" or the \"Company\") believes, expects, or ant...